Effect of dual compared to no or single Renin-Angiotensin System blockade on risk of renal replacement therapy or death in pre-dialysis patients: PREPARE-2 study

Current guidelines on hypertension treatment in chronic kidney disease (CKD) patients discourage combined angiotensin converting enzyme inhibitor (ACEi) and angiotensin II receptor blocker (ARB) use due to the risk of an increased kidney function decline. However, dual compared to single renin-angiotensin system (RAS) blockade may have more efficacy with regard to hypertension and proteinuria. Among incident pre-dialysis patients (CKD 4-5) we compared dual with no or single RAS blockade regarding kidney function decline, and risk of renal replacement therapy (RRT) or death.

Source: Journal of the American Society of Hypertension - July 21, 2017 Category: Cardiology Authors: Pauline W.M. Voskamp, Friedo W. Dekker, Merel van Diepen, Ellen K. Hoogeveen, PREPARE-2 Study Group Source Type: research